Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Hepatocellular 21Liver Neoplasms 2Differentiated Thyroid Cancer 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma 2Stomach Neoplasms 1Solid Tumor 1Recurrence 1Pancreatic Neoplasms 1Nasopharyngeal Carcinoma 1Locally Advanced Thyroid Gland Carcinoma 1Leukemia, Myeloid, Acute 1Hepatocellular Carcinoma with PVTT 1Esophageal Neoplasms 1Digestive System Neoplasms 1Diabetes Mellitus 1Cirrhosis, Familial, with Pulmonary Hypertension 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Carcinoma 1Biliary Tract Adenocarcinoma 1Biliary Malignant Tumors 1Advanced Solid Tumor 1

Interventions

Cisplatin 127Gemcitabine 71Radiotherapy, Intensity-Modulated 61toripalimab 39Capecitabine 37Docetaxel 36Fluorouracil 35Radiotherapy 24camrelizumab 23Drug Therapy 22nimotuzumab 18spartalizumab 13pembrolizumab 13nedaplatin 12Chemoradiotherapy 12sintilimab 11apatinib 11Induction Chemotherapy 11Immune Checkpoint Inhibitors 11tislelizumab 10Nivolumab 10Magnetic Resonance Spectroscopy 10Specimen Handling 9Radiation 9Cetuximab 9Carboplatin 9endostar protein 8Paclitaxel 8Bevacizumab 8anlotinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × donafenib × Clear all
NCT02698111 2023-05-08

Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2 Terminated
20 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡